Clinical Trials Logo

Arterial Ulcer clinical trials

View clinical trials related to Arterial Ulcer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05729334 Completed - Diabetic Foot Ulcer Clinical Trials

Clinical Investigation EUCLIDES-01 for the Calculation of the Area of Skin Lesions

Start date: November 28, 2022
Phase: N/A
Study type: Interventional

The aim of this clinical investigation is to collect skin lesion area data for the comparison of the agreement among the results obtained between the following three wound area measurement methods: - Ruler using the Kundin method, - Investigational software Clinicgram Euclides - Digital planimetry with Adobe Photoshop The clinical data retrieved in this study will allow the clinical validation of the safety and safety of the investigation software Clinicgram Euclides.

NCT ID: NCT05170984 Recruiting - Diabetic Foot Ulcer Clinical Trials

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

MATHCOW
Start date: February 10, 2022
Phase: N/A
Study type: Interventional

CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds. This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.

NCT ID: NCT03275831 Terminated - Venous Ulcer Clinical Trials

PluroGel on Wounds of Mixed Etiology

Start date: January 8, 2018
Phase: N/A
Study type: Interventional

A randomized controlled study (RCT) to investigate the topical effectiveness of PluroGel in healing venous and mixed aetiology leg ulcers. Patients with venous and mixed aetiology leg ulcers will be identified from hospital outpatient clinics. Willing patients meeting the inclusion and exclusion criteria will be consented and assessed in line with standard care. Participants will be randomized at Week 2 to receive either topical PluroGel or Intrasite gel (an alternative topical hydrogel product) if inclusion criteria is met.